Mukka Proteins IPO 2024: dates, price band, SEBI nod

SEBI clears Mukka Proteins to launch IPO

Mukka Proteins, a manufacturer of fish-based products, has received the Securities and Exchange Board of India’s (SEBI) go-ahead to raise funds through an initial public offering (IPO). The regulator issued an observation letter dated October 30, which in SEBI’s terminology signals approval to proceed with the public issue. The company’s updated draft red herring prospectus (DRHP) indicates that the IPO will be a fresh issue of up to 8 crore equity shares. The planned listing is on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The development marks a restart for the company’s capital markets plan after a previous IPO attempt in March 2022 that was later withdrawn.

What Mukka Proteins makes

Mukka Proteins manufactures fish meal, fish oil, and fish soluble paste, according to the DRHP-based disclosures cited in the available information. These products are typically used in animal feed and related industrial applications. The company is described as Karnataka-based, with references also noting Mangaluru. While the article does not detail customer segments or export exposure, the product profile places the company within the broader marine-products value chain.

The fresh issue structure: 8 crore shares, no OFS

The IPO is described as entirely a fresh issue of 8 crore equity shares, with no offer-for-sale (OFS) component mentioned. A fresh issue means the proceeds go to the company, subject to the stated utilisation plan. The book-built structure has been specified in the IPO details shared, and the price discovery will happen within a defined price band.

IPO size: early estimates versus final disclosed issue size

Earlier market sources cited in the information indicated the IPO size could be between ₹175 crore and ₹200 crore. Separately, the later IPO details state the Mukka Proteins IPO is a book-built issue of ₹224.00 crore. The total issue size is also presented as 80,000,000 shares aggregating to ₹224.00 crore. Taken together, the reporting suggests the market estimate preceded the finalised issue sizing shared in the IPO schedule and terms.

How the company plans to use the IPO proceeds

Going by the draft papers referenced, Mukka Proteins proposes to utilise up to ₹120 crore towards working capital requirements. It also proposes to invest up to ₹10 crore in its associate, Ento Proteins Pvt Ltd, for funding its working capital requirements. The remaining portion of the net fresh issue proceeds is to be used for general corporate purposes. These are the only explicitly stated end-uses in the provided content.

Key intermediaries: lead manager and registrar

Fedex Securities is named as the sole book-running lead manager for the issue. The registrar is mentioned as Cameo Corporate Services. These roles are central to the IPO process, covering book-building, compliance coordination, application processing, and allotment-related operations.

IPO dates, price band, lot size, and listing plan

The subscription window is specified as February 29, 2024 to March 4, 2024. The price band is set at ₹26 to ₹28 per share, with a face value of ₹1 per share. The minimum lot size for an application is 535 shares. The equity shares are proposed to be listed on BSE and NSE, and the listing date is specified as Thursday, March 7, 2024.

Mukka Proteins IPO snapshot

Allotment and post-issue schedule

The timeline provided includes the basis of allotment on Tuesday, March 5, 2024, followed by initiation of refunds on Wednesday, March 6, 2024. The cut-off time for UPI mandate confirmation is stated as 5 PM on March 4, 2024. These dates matter operationally for applicants, especially retail investors using UPI-based ASBA routes.

Key timeline for applicants

Background: the earlier IPO filing and refiling

The company had earlier filed draft papers with SEBI in March 2022, but later withdrew that attempt, as stated in the provided information. It subsequently refiled its draft IPO papers in June, with a separate reference noting the DRHP filing date as June 20, 2023. SEBI’s observation letter dated October 30 provided the regulatory clearance to move ahead. This sequence reflects how issuers often revisit timing, documentation, and market conditions before returning with an updated proposal.

Market impact: what the disclosed details tell investors

The most concrete investor-relevant signals in the provided information are structural: the issue is fully a fresh issue, the number of shares is up to 8 crore, and the price band is ₹26 to ₹28. The stated use of proceeds is also specific, led by up to ₹120 crore for working capital and up to ₹10 crore for investment in Ento Proteins for its working capital needs. The plan to list on both BSE and NSE indicates the company is targeting broad market access through India’s two primary stock exchanges.

Why the SEBI observation letter matters

In SEBI’s parlance, the observation letter is the effective nod for a company to float its public issue. The October 30 date is therefore a key milestone in the IPO’s regulatory journey. Combined with the later publication of the IPO calendar, it moves the transaction from a pre-filing phase to a market-facing issuance with defined terms, timelines, and intermediaries.

Conclusion

Mukka Proteins’ IPO plans have moved from regulatory clearance to a defined offering schedule, with a fresh issue of 8 crore shares, a ₹26-₹28 price band, and a February 29 to March 4, 2024 subscription window. The company has outlined working-capital focused utilisation, including funding needs at its associate Ento Proteins. With the listing planned on BSE and NSE on March 7, 2024, the next concrete milestones for applicants are the issue closing date, allotment on March 5, and the post-allotment timetable through listing.